Hunter Syndrome Treatment Market By Treatment Type Standard Enzyme Replacement Therapy, CNS-Directed Enzyme Replacement Therapy, Gene Therapy, Supportive and Symptom Management; By Disease Phenotype Neuronopathic Hunter Syndrome, Non-Neuronopathic Hunter Syndrome; By Diagnosis / Treatment Stage Presymptomatic / Newborn-Screened Pediatric Patients, Early Symptomatic Pediatric Patients, Advanced Neurologic Disease Patients, Long-Term Managed Patients; By Administration Model Weekly Intravenous Infusion, One-Time Gene Therapy Administration, Ex Vivo Stem-Cell Gene Therapy Administration, Supportive Care-Based Treatment; By End User Metabolic Specialty Centers, Hospitals, Pediatric Rare Disease Clinics, Home Infusion Providers; By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hunter Syndrome Treatment Market: CNS-Directed ERT, Newborn Screening, and Gene Therapy Redraw MPS II Care

The Global Hunter Syndrome Treatment Market will witness steady expansion at a CAGR of 6.4%, growing from USD 1.31 billion in 2025 to USD 2.02 billion by 2032, according to Strategic Market Research.

 

Hunter syndrome treatment is evolving from a primary focus on somatic disease management toward earlier intervention for neurologic involvement. For nearly two decades, treatment in the United States was largely centered on weekly intravenous idursulfase, which demonstrated benefits in walking capacity and several systemic clinical measures. However, its therapeutic impact on central nervous system manifestations remained limited because the molecule does not cross the blood–brain barrier.

 

The FDA approval of Denali’s Avlayah in 2026 marked a meaningful shift in the Hunter syndrome treatment landscape by introducing the first U.S.-approved therapy for neurologic manifestations in eligible pediatric patients. The approval was granted under the accelerated approval pathway, with cerebrospinal fluid heparan sulfate reduction accepted as the surrogate endpoint. Demonstration of confirmatory clinical benefit remains the key post-approval requirement.

 

Hunter syndrome has a very small diagnosed population, but each eligible patient represents high treatment intensity. FDA describes the condition as affecting about 500 people in the U.S., almost exclusively males, while HRSA estimates that fewer than 40 babies are born with MPS II each year in the country. Registry and newborn-screening evidence suggest that symptom-led diagnosis misses or delays early cases. HRSA’s evidence review reported a most-likely birth prevalence of 0.67 per 100,000 live births through clinical identification, compared with 1.6 per 100,000 in Illinois and Missouri newborn-screening data. Lifelong infusion burden, neurologic decline, high annual therapy cost, and one-time gene therapy potential make each diagnosed child commercially significant despite the small patient base.

 

Earlier Diagnosis Is Becoming a Treatment Access Issue

Hunter syndrome care depends heavily on the age at diagnosis. HRSA’s review, using Hunter Outcome Survey data, reported median symptom onset at about 1.5 years and median diagnosis at about 3.2 years. Severe neuronopathic disease can progress during this delay, and neurologic loss is harder to recover once developmental decline has advanced. Newborn screening, genetic confirmation, and fast referral to metabolic specialists therefore carry direct treatment value, especially for therapies intended for use before advanced neurologic impairment.

U.S. newborn-screening programs are becoming an important access pathway for MPS II therapies. HRSA notes that screening measures iduronate-2-sulfatase enzyme activity and sometimes glycosaminoglycan levels. Its evidence review estimated incremental screening costs at about USD 2 to USD 6 per infant. Implementation is still operationally demanding. Around 62% of surveyed newborn-screening programs expected test validation, equipment purchases, staffing, and follow-up protocol development to take one to three years. Drug developers benefit when states move from symptom-led diagnosis to screening-led diagnosis because eligible children can enter treatment before neurologic decline becomes advanced.

Asia-Pacific evidence supports the same early-treatment argument. HRSA’s review reported Japan and Taiwan prevalence based on clinical identification at 0.84–1.07 per 100,000 births, compared with 0.26–0.64 per 100,000 births elsewhere after excluding outlier estimates. Taiwan newborn-screening literature also shows MPS II accounting for a large share of mucopolysaccharidosis diagnoses in several Asian countries, including Japan and South Korea. Pediatric metabolic centers, confirmatory enzyme testing, genetic counseling, and early enzyme replacement access are therefore especially important in markets with established newborn-screening programs.

 

Idursulfase Still Anchors Somatic Care

Idursulfase remains the established treatment reference because it has long clinical use, payer familiarity, and defined weekly dosing. EMA lists Elaprase at 0.5 mg/kg body weight once weekly by intravenous infusion for long-term treatment of Hunter syndrome. The pivotal 52-week study enrolled 96 patients aged 5 to 31 years and showed benefit on a composite endpoint of 6-minute walk distance and percent predicted forced vital capacity. The 6-minute walk test improved by 43.3 meters with idursulfase, compared with 8.2 meters with placebo. Urine GAG levels, liver volume, and spleen volume also improved.

Takeda’s Elaprase franchise is supported by established infusion networks, reimbursement experience, home-infusion use in selected patients, and physician familiarity in rare metabolic disease clinics. Observational Hunter Outcome Survey data also support its continuing role. A peer-reviewed analysis reported median survival of 33.0 years in idursulfase-treated patients, compared with 21.2 years in untreated patients, although the result was observational rather than randomized.

Idursulfase faces its largest limitation in neuronopathic disease. GeneReviews states that idursulfase does not cross the blood–brain barrier, so CNS benefit is not expected, although somatic features may still improve in patients with severe neurologic involvement. Progressive cognitive and behavioral decline often defines the most severe Hunter syndrome cases more than liver enlargement, joint stiffness, airway disease, or mobility decline. Standard ERT can remain central for somatic control, but CNS-penetrant treatment is setting the new benchmark for newly diagnosed neuronopathic patients.

 

Elaprase’s USD 650 Million Base Sets the Revenue Hurdle for CNS-Directed MPS II Therapies

Elaprase gives the Hunter syndrome treatment market a validated revenue floor rather than a theoretical orphan-drug opportunity. Takeda’s idursulfase franchise generated JPY 97.2 billion in FY2024, or about USD 642 million, up 6.1% from the prior year. First-quarter FY2025 sales reached about USD 185 million, keeping Elaprase on a roughly USD 650 million annualized global run rate. Growth has been supported by Takeda’s Growth and Emerging Markets business and currency effects, while North America remains the highest-value region because rare-disease reimbursement and long-term ERT use are already established.

Elaprase’s revenue is outsized relative to the patient pool. Royalty Pharma’s tividenofusp alfa materials cite more than 2,000 Hunter syndrome patients globally and more than 500 in the U.S., while also referencing Elaprase at about USD 650 million in global sales. A therapy serving only a few thousand patients can therefore support a mid-hundreds-of-millions revenue base when treatment is lifelong, weekly, weight-based, and reimbursed as an ultra-rare disease therapy.

The broader enzyme replacement therapy market, estimated at approximately USD 17.3 billion, provides MPS II therapy developers with an important reference point for pricing strategy, payer acceptance, infusion-based care infrastructure, and the long-term economics of chronic rare-disease management. Elaprase remains aligned with the conventional ERT treatment paradigm, delivering exogenous iduronate-2-sulfatase through weekly intravenous infusion to address systemic enzyme deficiency. However, its inability to cross the blood-brain barrier limits its impact on central nervous system manifestations, creating a clinically significant and commercially valuable opportunity for therapies capable of preserving neurologic function in addition to reducing somatic glycosaminoglycan accumulation.

Avlayah is entering a treatment landscape in which payer willingness to fund high-cost enzyme replacement therapy has already been established by the incumbent standard of care. The FDA approved tividenofusp alfa as a once-weekly intravenous infusion for the treatment of neurologic manifestations of Hunter syndrome in patients initiated on therapy before the onset of advanced neurologic impairment. Denali positions Avlayah as a transferrin receptor-enabled biologic designed to cross the blood-brain barrier via receptor-mediated transcytosis. As a result, the product is not being introduced into an untreated market, but rather into a premium therapeutic segment where its commercial opportunity depends on shifting eligible high-value patients from conventional ERT toward CNS-directed enzyme delivery.

Royalty Pharma’s forecast puts the Avlayah opportunity close to the Elaprase revenue base. Its tividenofusp alfa presentation cites consensus global peak sales of USD 575 million by 2035. Royalty Pharma also committed up to USD 275 million in royalty funding to Denali, including USD 200 million upfront and USD 75 million tied to EMA approval by the end of 2029. The deal gives Avlayah a financial validation point before full global commercialization and shows that investors see neurologic MPS II treatment as a large enough opportunity to support royalty-backed financing.

Avlayah’s uptake will depend on switching economics, not only new-patient starts. The U.S. has more than 500 Hunter syndrome patients, but HRSA estimates fewer than 40 babies are born with MPS II each year. Newborn screening can improve early diagnosis, but near-term sales will also depend on whether metabolic specialists move eligible children from Elaprase to Avlayah before advanced neurologic impairment. Payers will assess CSF heparan sulfate reduction, neurologic trajectory, infusion reactions, antibody profile, and confirmatory trial progress before allowing broad substitution.

Gene therapy creates the larger revenue disruption. Elaprase monetizes MPS II through lifelong weekly infusion. Avlayah preserves the weekly ERT model but adds CNS delivery. NAVSUNLI/RGX-121 and stem-cell gene therapy programs could shift lifetime value into one-time treatment if they show durable enzyme expression, CNS substrate reduction, and neurodevelopmental stabilization. Elaprase’s USD 650 million global base therefore becomes the benchmark every advanced MPS II therapy must beat on durability, neurologic benefit, access, and payer acceptance.

 

Avlayah Moves CNS Treatment Into the Approved Market

Avlayah gives Denali the first U.S. label for neurologic manifestations of Hunter syndrome. FDA granted accelerated approval for presymptomatic or symptomatic pediatric patients weighing at least 5 kg before advanced neurologic impairment, based on reduced cerebrospinal fluid heparan sulfate. The label also states that Avlayah is not recommended in combination with other enzyme replacement therapies for Hunter syndrome. That wording makes switching strategy more important than add-on use.

The approval package rests on biomarker depth. In Trial 1, 47 male pediatric patients aged 3 months to 13 years received Avlayah. Among 44 patients with Week 24 measurements, CSF heparan sulfate declined by a mean 91% from baseline, and 93% had CSF HS levels below the upper limit of normal at Week 24. Urine heparan sulfate declined 86%, urine dermatan sulfate 91%, and total urine GAGs 57% at Week 24. FDA also notes that the relationship between these biomarker changes and clinical response has not been established, keeping clinical durability central to post-approval evaluation.

Safety management will affect uptake in metabolic centers and payer reviews. FDA label data show infusion-associated reactions in 87% of Avlayah-treated pediatric patients, anemia in 51%, and anti-drug antibodies in 100% of treated patients after 19 to 219 weeks of exposure. Neutralizing antibodies that inhibit enzyme activity were detected in 87% of patients. Physicians may accept close monitoring when the alternative is neurologic decline, but long-term use will depend on manageable infusion reactions, antibody impact, and confirmatory evidence.

Denali’s Phase 2/3 COMPASS trial will shape the product’s durability in the U.S. and its global filing prospects. The company states that continued approval may depend on verification of clinical benefit in COMPASS, where participants are randomized 2:1 to Avlayah or idursulfase across North America, South America, and Europe. Positive data would strengthen the case for early CNS-directed ERT. Delayed or weak clinical results would keep Avlayah exposed to accelerated-approval risk.

 

Gene Therapy Could Challenge Lifelong Weekly Infusion

Regenxbio’s NAVSUNLI/RGX-121 is the leading one-time gene therapy program in MPS II and the strongest potential challenge to chronic weekly ERT economics. Hunter syndrome affects about 500 people in the U.S., and fewer than 40 babies are born with the condition each year. A durable one-time therapy that preserves neurologic function could move a meaningful share of lifetime treatment value away from recurring infusions and toward upfront gene therapy.

Regulatory risk remains high. FDA declined approval in February 2026 and cited concerns around trial design, patient eligibility, external-control comparability, and the use of CSF HS D2S6 as a surrogate endpoint. Regenxbio later reported that FDA requested a Type A meeting and allowed a potential BLA resubmission using existing longer-term biomarker and clinical data. Ultra-rare pediatric diseases may still fit accelerated approval when randomized trials are difficult, but sponsors must prove that biomarker reduction is durable, interpretable, and clinically meaningful.

Gene therapy must show more than substrate reduction. Standard idursulfase does not cross the blood–brain barrier, while Avlayah showed a mean 91% reduction in CSF heparan sulfate at Week 24. A one-time therapy needs comparable CNS substrate control with longer durability and less treatment burden. Sustained enzyme expression, neurodevelopmental stabilization, reduced dependence on chronic ERT, and acceptable long-term safety will determine whether gene therapy can compete with CNS-penetrant ERT.

The UK stem-cell gene therapy program gives the field another route. LifeArc and the University of Manchester are supporting a Phase I/II study at Royal Manchester Children’s Hospital that plans to recruit five boys aged 3 to 22 months with neuronopathic Hunter syndrome. The therapy uses autologous hematopoietic stem cells modified with a lentiviral vector carrying a functional IDS gene. The enzyme is engineered to cross the blood–brain barrier, with the goal of long-term enzyme production after a single treatment.

Infant treatment is clinically important because neurologic preservation is more realistic before major developmental decline. HRSA data show median symptom onset at about 1.5 years and median diagnosis at about 3.2 years. Gene therapy adoption may therefore depend on newborn screening and rapid referral pathways as much as on product performance. Without early identification, patients may reach treatment after the window for meaningful neurologic preservation has narrowed.

Payers and physicians will judge gene therapy through long-term benefit, not only early biomarkers. Evidence expectations will include neurodevelopmental stability, conditioning toxicity, vector safety, manufacturing reliability, and long-term oncogenicity surveillance. Families will weigh one-time treatment risk against weekly infusions over many years. Gene therapy has the highest disruption potential in Hunter syndrome, but treatment in very young children raises the evidence burden.

 

BBB-Penetrant ERT Is Becoming the Main Product Battleground

CNS delivery is reshaping competition in MPS II. Avlayah uses Denali’s brain-penetrant enzyme replacement approach. JCR Pharmaceuticals’ pabinafusp alfa/JR-141 uses an anti-human transferrin receptor antibody fusion design to cross the blood–brain barrier. JCR reported completion of target enrollment in its global Phase III trial across the U.S., Latin America, and Europe in July 2025, while ClinicalTrials.gov identifies STARLIGHT as a Phase III study in MPS II sponsored by JCR.

JR-141 could become the most direct global competitor to Avlayah in BBB-penetrant ERT. JCR previously launched pabinafusp alfa in Japan as IZCARGO and then moved into broader global development through STARLIGHT. Positive global Phase III data would give physicians another CNS-directed enzyme option and create direct competition around neurologic outcomes, infusion burden, safety, antibody profile, and payer coverage.

Denali and JCR are also using Hunter syndrome as a proof point for brain-delivery technology in lysosomal storage disorders. Strong MPS II outcomes could support confidence in BBB-penetrant enzyme platforms for other pediatric neurodegenerative metabolic diseases. Weak or inconsistent outcomes would push more development attention toward gene therapy, intrathecal approaches, or other delivery technologies.

 

Regional Access Depends on Screening and Reimbursement

The U.S. is the highest-value market because it combines premium rare-disease pricing, accelerated approval pathways, established ERT reimbursement, metabolic-specialist networks, and growing newborn-screening momentum. FDA estimates about 500 people live with Hunter syndrome in the country. HRSA estimates fewer than 40 babies are born with MPS II each year. High-cost treatment demand is concentrated in a small number of children who can be identified before advanced neurologic impairment.

Screening can expand the treated population by finding children earlier than symptom-led diagnosis. HRSA evidence shows clinical identification at about 0.67 per 100,000 live births, compared with 1.6 per 100,000 live births in Illinois and Missouri newborn-screening data. Avlayah will also test payer willingness to fund CNS-directed ERT before irreversible neurologic decline. Reuters reported a list price of USD 5,200 per 150 mg vial, with weekly weight-based dosing. Coverage decisions will likely focus on age at initiation, neurologic status, biomarker response, switching from Elaprase, and continued evidence from confirmatory trials.

Europe is likely to remain more restrictive. EMA and national health-technology assessment bodies generally require stronger comparative evidence and long-term value justification for high-cost pediatric rare-disease therapies. Products relying on surrogate biomarkers will face close review. Denali’s COMPASS trial and JCR’s STARLIGHT trial will matter for European adoption because reimbursement will depend on neurodevelopmental outcomes, safety, treatment burden, and durability. Early use will likely concentrate in specialist metabolic centers in Germany, France, Italy, Spain, and the UK.

Japan and Taiwan are strategically important because identified disease burden is higher than in many Western markets. HRSA evidence reported clinical prevalence of 0.84 to 1.07 per 100,000 births in Japan and Taiwan, compared with 0.26 to 0.64 per 100,000 births in other regions after excluding outlier estimates. Japan already has local experience with pabinafusp alfa, giving the country an early position in BBB-penetrant ERT. Taiwan’s newborn-screening activity can support earlier identification. South Korea, China, Australia, and Southeast Asian markets will depend more heavily on screening coverage, reimbursement policy, and access to specialist metabolic care.

 

Competitive Positioning Is Shifting from Infusion Presence to Neurologic Proof

Takeda’s Elaprase remains the established somatic ERT reference. Its position is supported by long clinical experience, weekly dosing familiarity, and evidence across walking capacity, pulmonary function, urinary GAGs, liver volume, and spleen volume. Takeda is unlikely to lose its role immediately, but newly diagnosed neuronopathic patients could shift toward CNS-penetrant products if neurologic evidence, payer coverage, and clinician confidence improve.

Denali now holds the first U.S. CNS-directed label. Avlayah’s commercial performance depends on confirmed clinical benefit, management of infusion reactions and immunogenicity, and payer acceptance of high-cost treatment before advanced neurologic impairment. The label language against combination with other ERTs makes patient switching and first-line selection central to its uptake.

Regenxbio offers a one-time treatment model that could challenge lifelong weekly infusion if NAVSUNLI secures approval and long-term data support durable neurologic and biomarker benefit. Regulatory volatility remains the main constraint because the program moved through clinical hold, complete response, and renewed accelerated-approval alignment within the same year.

JCR’s pabinafusp alfa is the most credible BBB-penetrant ERT competitor outside Denali. Full enrollment in global Phase III gives the program a mature evidence path. A successful global filing would create a more competitive CNS-directed ERT category, with products differentiated by neurologic outcomes, antibody profile, safety management, infusion logistics, and long-term developmental data.

 

Analyst View

Hunter syndrome treatment is being reshaped by newborn screening, CNS-penetrant enzyme delivery, and one-time gene therapy. Newborn screening can move diagnosis into infancy, when neurologic preservation has the highest clinical value. Avlayah has changed the U.S. treatment category by turning CSF heparan sulfate reduction into an approvable surrogate endpoint for neurologic Hunter syndrome. Confirmatory clinical benefit remains the key post-launch test. Gene therapy could challenge lifelong infusion economics, but regulatory confidence, long-term safety, and neurodevelopmental durability remain unresolved.

The strongest market indicators are state-level newborn-screening expansion, age at treatment initiation, Avlayah uptake versus Elaprase switching, COMPASS confirmatory progress, NAVSUNLI BLA resubmission timing, JCR STARLIGHT results, payer criteria for presymptomatic children, infusion-center capacity, antibody impact, and long-term neurodevelopmental outcomes. Suppliers with credible CNS delivery, early-treatment data, registry support, and reimbursement strategy will be better positioned than companies limited to somatic disease control.

 

Hunter Syndrome Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.31 Billion
Revenue Forecast in 2032	USD 2.02 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Phenotype, By Diagnosis / Treatment Stage, By Administration Model, By End User, By Geography
By Treatment Type	Standard Enzyme Replacement Therapy, CNS-Directed Enzyme Replacement Therapy, Gene Therapy, Supportive and Symptom Management
By Disease Phenotype	Neuronopathic Hunter Syndrome, Non-Neuronopathic Hunter Syndrome
By Diagnosis / Treatment Stage	Presymptomatic / Newborn-Screened Pediatric Patients, Early Symptomatic Pediatric Patients, Advanced Neurologic Disease Patients, Long-Term Managed Patients
By Administration Model	Weekly Intravenous Infusion, One-Time Gene Therapy Administration, Ex Vivo Stem-Cell Gene Therapy Administration, Supportive Care-Based Treatment
By End User	Metabolic Specialty Centers, Hospitals, Pediatric Rare Disease Clinics, Home Infusion Providers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Expansion of newborn screening programs, increasing demand for CNS-targeted therapies, limitations of conventional enzyme replacement therapy in neurological disease, advancement of gene therapy platforms, rising investment in rare pediatric disease treatments
Customization Option	Available upon request